Actively Recruiting
Phase 2 Open-Label Study Evaluating Safety, Tolerability, and Efficacy of MK-1045 in Blood Cancers Affecting B-Cells
Led by Merck Sharp & Dohme LLC · Updated on 2026-11-04
60
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating new treatments for people with B-cell cancers, specifically chronic lymphocytic leukemia CLL and small lymphocytic lymphoma SLL. These cancers affect B-cells found in the blood, bone marrow, or lymph nodes. This phase 2 trial aims to study the safety and tolerability of the drug MK-1045, as well as to measure how many participants respond to the treatment by showing reduced cancer signs or fewer cancer cells. Participants will receive MK-1045 through an intravenous infusion in a step-up dosing schedule beginning with low doses in the first cycle and increasing to a target weekly dose for up to about two years. Those who respond completely after at least three 4-week treatment cycles may switch to dosing every two weeks. Premedications like acetaminophen, diphenhydramine, and dexamethasone will be used, and rescue medications such as tocilizumab or its biosimilar and siltuximab are available if needed. During the study, participants will undergo assessments for dose-limiting toxicities, adverse events, and treatment discontinuations due to side effects, tracked over months to years. Researchers will also measure how well the drug is tolerated, the objective response rate, and various drug concentration levels in the body. The total study duration extends up to approximately 66 months, with regular monitoring to evaluate treatment safety and effectiveness.
CONDITIONS
Brief Title
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here